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Results: Median age was 27y (range: 0.8-66y) and the ma-
jority were men (58%). A total of 36 (49%) patients had CMV
infection out of 74 (78%) CMV seropositive recipients. CMV
infection occurred at a median of 38 days after CBT (range: -1
- +927d). Most patients had GvHD (56%), received steroids
(34%), and immunosuppressive therapy (87%), mainly
tacrolimus prior to CMV infection. Whether CBT recipients
received CMV prophylaxis (between day -10 to -3) or not, the
incidence of CMV reactivationwas not statistically signiﬁcant
(37% vs. 43%, respectively). Progression to CMV end organ
disease occurred in 6 patients at an incidence of 6% and
mainly affected the gastrointestinal (GI) tract. CMV-associ-
ated mortality occurred in only 1 patient with CMV pneu-
monia. Non relapse related mortality occurred in 25 (26%) of
CBT recipients and was not different when stratiﬁed by CMV
serostatus and CMV reactivation. Univariate analysis
revealed that CMV-seropositive recipients with leukemia
had higher risk of developing CMV infection compared to
seropositive patients with lymphoma (83% vs.17%; p¼0.039).Figure 1. No signiﬁcant difference in day 0 F-ara-A levels between patients with vs w
therapy (25,000 IU/mL plasma), post-transplant lymphoproliferative disorder (PTLD), r
p was >0.05 (range,0.22-0.78). Mann-Whitney-Wilcoxon test was used. “cGVHD NSTAmong CMV-seropositive recipients, more pts with CMV
infection were transferred to ICU (56% vs. 34%; p¼0.046) and
needed mechanical ventilation (36% vs. 21%; p¼0.121). MVA
did not yield any signiﬁcant predictors of CMV infection.
Conclusion: CMV infection after CBT is common and occurs
early on after transplant. Patients with leukemia are at
higher risk of this complication after CBT. Interestingly, CMV
end-organ disease was not common and mainly affected the
GI tract in this patient population.346
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Background: Fludarabine is a common constituent of con-
ditioning for hematopoietic cell transplantation (HCT). It is a
prodrug that is dephosphorylated in plasma to its measur-
able metabolite, F-ara-A, which after intracellular rephos-
phorylation interferes with DNA replication, transcription
and translation, and induces apoptosis.
Due to variable renal clearance, F-ara-A levels on day 0 are
variable. The clinical relevance of the F-ara-A persisting in
plasma is unknown. The goal of this study was to assess the
relationship between F-ara-A levels on day 0 and clinical
outcomes including GVHD, infections, relapse and death.
Patients and Methods: We included 166 consecutive
patients undergoing ﬁrst allogeneic transplantation of ﬁl-
grastim-mobilized blood stem cells for a hematologic ma-
lignancy between December 2008 and 2012. Conditioning
was myeloablative, and included ﬂudarabine (50 mg/m2
daily from days -6 to -2), busulfan and antithymocyte glob-
ulin. Additional GVHD prophylaxis included methotrexate
and cyclosporine. The interval between the last ﬂudarabine
dose and graft infusion was 48-72 hours. F-ara-A serum
levels were measured using mass spectrometry.
Results: In univariate analyses, there was no difference in
median F-ara-A levels between patients who did vs did not
develop acute GVHD grade 2-4, acute GVHD grade 3-4, any
chronic GVHD, chronic GVHDneeding systemic therapy (NST),
CMV reactivation above our threshold for preemptive therapy
(25,000 IU/mL), post-transplant lymphoproliferative disorder
(PTLD), relapse, death or non-relapse death (Figure 1).
In multivariate analyses, there was no difference in the
likelihood of developing any one of the outcomes between
patients whose F-ara-A level was above vs below median (14
ng/mL). We also assessed for differences in the likelihood of
developing each outcome between patients with levels in
the fourth quartile (21-104 ng/mL) vs the ﬁrst quartile (1-9
ng/mL). Again, in this analysis, there was no difference for
any outcome.
We also noted a weak correlation between F-ara-A levels
on day 0 and the day of neutrophil engraftment (r¼0.16,
p¼0.04), and a trend towards more bacterial infections in
patients with F-ara-A levels in the fourth vs ﬁrst quartile.
Discussion: The results suggest that there is no or minimal
impact of day 0 F-ara-A levels on clinical outcomes. This may
be due to the fact that F-ara-A levels on day 0 were relatively
low (1-104 ng/mL, median 14 ng/mL) compared to levels 1-4
hours after ﬂudarabine infusion (w1,000 ng/mL).
Conclusion: Day 0 F-ara-A levels are highly variable (1-104
ng/mL), likely due to variable renal function. Given that we
found no association between the day 0 levels and clinical
outcomes we do not support delaying graft infusion until F-
ara-A level has dropped below a certain level, as long as the
last ﬂudarabine dose is given within 48 hours of graft infu-
sion and to patients with normal renal function.347
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Background: Allogeneic hematopoietic stem-cell trans-
plantation (allo-HSCT) is a potentially curative treatment for
a variety of hematologic malignancies and nonmalignant
hematologic disorders. However, only about a third of
candidates for allo-HSCT have HLA-matched siblings. For
patients who lack HLA-matched siblings, partially HLA-mis-
matched (haploidentical) related donors are good alternative
sources of stem cells for allo-HSCT. In this retrospective,
single center study we evaluated safety and efﬁcacy of hap-
loidentical allo-HSCT compared to those of HLA-matched
allo-HSCT in patients with acute leukemia.
Methods: A total of 94 acute leukemia patients with a mean
age of 37 years who underwent allo-HSCT between June
2010 and November 2012 were analyzed. All patients
received Cyclophosphamide (Cy) 50 mg/kg i.v. on days +3
and +4. Pharmacologic prophylaxis of GvHD with cyclo-
sporine-A (CsA) and mycophenolate mofetil (MMF) was not
initiated until day +5 to avoid blocking Cy-induced tolerance.
All patients received CsAwhich was initiated at a dose of 400
mg/day, and then adjusted according to the plasma levels. If
there was no GvHD, it was tapered off by day +180. In
addition to CsA, all haploidentical allo-HSCT recipients
received MMF until day +35 at a dose of 1 gr/day.
Results: There were no signiﬁcant differences in age, sex,
type of acute leukemia, disease status up-front HSCT, or
transplant characteristics between the groups except a
higher median number of stem cells infused in hap-
loidentical group (p¼0.002). The median follow-up was 194
(range 88-372) days for haploidentical group and 210 (range
105-417) days for HLA-matched group. 98% of the patients
engrafted. The median time to neutrophil and thrombocyte
engraftments were signiﬁcantly longer in the haploidentical
group compared to the HLA-matched group (neutrophil
engraftment; 20 days vs 16 days, respectively, p¼ 0.006)
(thrombocyte engraftment; 18 days vs 16 days, respectively,
p¼0.015). The incidence of acute GvHD >¼ 2 was 56% in
haploidentical group and 19% in HLA-matched group
(p¼0.001). The incidence of documented viral infections was
signiﬁcantly higher in the haploidentical group compared to
the HLA-matched group (42% vs 11%, respectively, p¼0.001).
The relapse rates as well as the overall mortality rates (at 100
days and 1 year) were not signiﬁcantly different between the
two groups.
Conclusion: Our results suggest that haploidentical allo-
HSCT is a safe treatment modality in patients with acute
leukemia who lack HLA-matched siblings. The major prob-
lems are seems to be viral infections and acute GvHD. Future
challenges remain in improving post-transplant immune
reconstitution and ﬁnding the best approach to reduce the
incidence and severity of GvHD and infections, while pre-
serving graft-versus-leukemia effect to prevent the recur-
rence of the underlying disease.348
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